menu search

IKT / Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the first quarter ended March 31, 2023, on Monday, May 15, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. Read More
Posted: May 8 2023, 08:05
Author Name: PRNewsWire
Views: 073142

IKT News  

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

By PRNewsWire
August 22, 2023

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

BOSTON and ATLANTA , Aug. 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmace more_horizontal

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

By PRNewsWire
May 8, 2023

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceuti more_horizontal

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

By PRNewsWire
April 21, 2023

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

BOSTON and ATLANTA , April 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmace more_horizontal

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

By PRNewsWire
March 23, 2023

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

BOSTON and ATLANTA , March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmac more_horizontal

Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?

By InvestorPlace
January 26, 2023

Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?

Inhibikase Therapeutics (NASDAQ: IKT ) stock is falling on Thursday after the company announced a registered direct offering and private placement. St more_horizontal

Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 15, 2022

Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2022 Earnings Conference Call November 15, 2022 8:00 AM ET Company Participants Alex Lobo – Stern Inv more_horizontal

Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference

By PRNewsWire
March 8, 2022

Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference

BOSTON and ATLANTA, March 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company de more_horizontal


Search within

Pages Search Results: